Thank you to everyone who joined #IMS24, both in person and virtually. Save the date for next year's conference, taking place September 17-20 in Toronto, Canada. We look forward to seeing you in 2025!?
International Myeloma Society
非盈利组织
Boston，MA 4,001 位关注者
Fostering Clinical and Experimental Scientific Exchange
关于我们
The International Myeloma Society (IMS) promotes education, research and clinical care globally by: Building a global myeloma community Educating for today and the future Fostering clinical and translational research in myeloma Assuring clinical excellence worldwide The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide. The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners. IMS is governed by a Board of Directors representing practices from around the world, and encourages and promotes the study of this expanding field through its biannual International Myeloma Workshop.
- 网站
-
https://www.myelomasociety.org/
International Myeloma Society的外部链接
- 所属行业
- 非盈利组织
- 规模
- 1 人
- 总部
- Boston，MA
- 类型
- 非营利机构
地点
-
主要
获取路线
US，MA，Boston
International Myeloma Society员工
动态
-
The IMS will be accepting applications for the International Myeloma Society (IMS) and Paula and Rodger Riney Foundation Translational Research Award until January 31, 2025. Learn more about eligibility requirements on our website: https://lnkd.in/eUh3_S85
-
-
The IMS will be accepting applications for the Career Development Award until January 31, 2025. Learn more about eligibility requirements on our website: https://lnkd.in/edqhtSmY
-
-
Don't forget, you can still access #IMS24 meeting content. If you registered for either in-person or virtual, login to the virtual platform to review all recorded sessions. https://lnkd.in/earShsAB
-
-
Highlights from the closing day of the 21st Annual IMS Meeting! #IMS24
-
-
Please remain in Pavilion 3 after the Novel Biomarkers - Personalizing Therapy in Myeloma session for the Closing Ceremonies at #IMS24
-
-
NDMM Session highlights need for improved clinical trial structure infrastructure and clinician education in Latin America to address disparities in access to MM treatments/trials. #IMS24
-
-
Philippe Moreau, MD, reviewed key challenges, and questions to be answered in ongoing studies - MRD-adapted therapy, MRD as a 1° endpoint in NDMM trials. #IMS24
-
-
In this episode?of IMSound, gain insight?into the first results from the eagerly awaited MIDAS study from Aurore Perrot, MD, PhD, Dr. Perrot describes the study rationale, design, and key findings - IsaKRd yielded exceptionally high MRD-negativity rates. https://bit.ly/4eGqj83 #IMS24
-